Format

Send to

Choose Destination
Curr Surg. 2006 Sep-Oct;63(5):334-7.

Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.

Author information

1
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Abstract

Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

PMID:
16971205
DOI:
10.1016/j.cursur.2006.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center